Callan Family Office LLC Invests $3.98 Million in Elanco Animal Health Incorporated $ELAN

Key Points

• Callan Family Office initiated a $3.98 million position in Elanco Animal Health, purchasing 161,687 shares during the second quarter. Institutional investors collectively own 97.48% of the company.
• Elanco insiders bought 63,198 shares worth approximately $1.47 million in the latest quarter, including purchases by the CFO and another senior executive.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $29.09 price target. The company also exceeded quarterly expectations, reporting $0.34 EPS and $1.37 billion in revenue, up 10.2% year over year.

Callan Family Office LLC bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 161,687 shares of the company's stock, valued at approximately $3,979,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ELAN. Peak Retirement Planning Inc. bought a new position in Elanco Animal Health during the fourth quarter valued at $2,756,000. Norges Bank bought a new stake in shares of Elanco Animal Health in the 4th quarter worth about $32,415,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Elanco Animal Health in the 1st quarter worth about $66,390,000. Geneos Wealth Management Inc. lifted its holdings in shares of Elanco Animal Health by 3,358.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 202,747 shares of the company's stock worth $4,852,000 after acquiring an additional 196,884 shares during the last quarter. Finally, OP Asset Management Ltd purchased a new position in shares of Elanco Animal Health during the 1st quarter worth about $8,171,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Shiv O'neill purchased 3,998 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider owned 87,832 shares of the company's stock, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert M. Vanhimbergen purchased 4,200 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $23.08 per share, with a total value of $96,936.00. Following the purchase, the chief financial officer directly owned 137,516 shares of the company's stock, valued at approximately $3,173,869.28. This represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several analyst reports. TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, June 18th. Morgan Stanley boosted their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 22nd. Piper Sandler reaffirmed an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Weiss Ratings downgraded Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday. Finally, KeyCorp increased their price target on Elanco Animal Health from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.09.

Elanco Animal Health Trading Up 2.1%

NYSE ELAN opened at $24.05 on Friday. The stock has a market cap of $12.02 billion, a PE ratio of -58.66, a PEG ratio of 1.41 and a beta of 1.67. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company's 50-day moving average price is $24.56 and its 200-day moving average price is $24.01. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source